Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Contract Pharma16h
TriLink, Avantor Team Up to Expand Nucleic Acid Access in EMEA
TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...
Avantor, TriLink BioTechnologies partner on nucleic acid solutions in Europe
TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
The Armenian Reporter2d
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Kurt Oreshack Sells 25,000 Shares
General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of ...
bovnews5d
Maravai Lifesciences Holdings Inc (MRVI) Stock’s -0.03% Decrease This Year: What’s the Story?
Maravai Lifesciences Holdings Inc (MRVI) stock saw a decline, ending the day at $5.5 which represents a decrease of $-0.11 or -1.96% from the prior close of $5.61. The stock opened at $5.79 and ...
Business Wire6d
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...
Maravai LifeSciences expands mRNA manufacturing with new acquisition
SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...